Precision Medicine in Inflammatory Bowel Diseases
Open Access
- 13 April 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
During the last decades, a better understanding of the mechanisms sustaining the pathogenic process in inflammatory bowel diseases (IBD) has contributed to expand the therapeutic armamentarium for patients with these disorders. Alongside with traditional therapies, monoclonal antibodies against tumor necrosis factor-α, the interleukin (IL)-12/IL-23 p40 subunit and the α4β7 integrin, and tofacitinib, a small molecule inhibiting intracellular pathways downstream to cytokine receptors, have entered into the clinic. However, these drugs are not effective in all patients and some responders can lose response over time. Such a therapeutic failure is, at least in part, dependent on the fact that, in IBD, the tissue damage is driven by simultaneous activation of multiple and distinct immune-inflammatory signals and the detrimental mucosal immune response changes over time even in the same patient. Therefore, personalized approaches aimed at identifying which patient should be treated with a specific drug at a precise time point are worth pursuing. A such approach has the advantage to improve efficacy of the drug and limit adverse reactions, thereby improving quality of the life of the patients and reducing costs. In this review, we summarize all the available evidence about the possible role of precision medicine in IBD.Keywords
This publication has 44 references indexed in Scilit:
- Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn’s DiseasePLOS ONE, 2013
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and TherapyGastroenterology, 2012
- Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitisJournal of Clinical Investigation, 2011
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2009
- Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 ReceptorNew England Journal of Medicine, 2009
- Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitisGut, 2009
- The inflammasome in pathogen recognition and inflammationJournal of Leukocyte Biology, 2007
- Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2005
- Immunity, Inflammation, and Allergy in the GutScience, 2005